REPLIGEN CORP — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 17/100
What the filing says
Repligen Corporation (REPLIGEN) has entered into a definitive merger agreement to acquire BioLife Solutions, Inc. dated July 21, 2026. Under the agreement, each BioLife share will convert into 0.1442 Repligen shares plus $11.25 cash. BioLife has 48.9M shares outstanding (as of July 17, 2026 measurement date); the transaction implies a total consideration of approximately $1.0B in stock plus $550M in cash, subject to adjustment if Repligen stock issuance exceeds 19.9% of outstanding shares (triggering cash-in-lieu conversion). The deal is structured as a tax-free reorganization and is expected to close within months pending stockholder approval and regulatory clearance.
Why this rating
At ~$1.55B total deal value relative to Repligen's $6.0B market cap (26% of buyer size), this is material but routine M&A. No transformational element apparent from merger agreement terms alone.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.